Medicines

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.

Shares of Medicines Co. MDCO, +12.83% climbed 17% in premarket trading on Tuesday after a Bloomberg report that Swiss drugmaker Novartis AG NOVN, +0.63% NVS, +0.32% could be mulling an offer for the maker of cholesterol drugs.

Medicines Co. shares jump 17% in premarket after report of potential Novartis offer

Clinical data for cholesterol-lowering drug inclisiran looks good.

Here's Why The Medicines Company Moved Higher Today

Shares of The Medicines Company popped Monday after the biotech company's RNA interference approach to cholesterol treatment proved itself over 18 months. The drug also proved to be safe.

Biotech Stock Nears Record High On Gene-Silencing Cholesterol Drug

The Medicines Company (MDCO) reports detailed data from the phase III ORION-10 study on its lead candidate inclisiran to treat patients with ASCVD.

Medicines Company Posts Full Inclisiran Data From ASCVD Study

The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.

Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss

The Medicines Company (MDCO) CEO Mark Timney on Q3 2019 Results - Earnings Call Transcript

Medicines Co. (MDCO) delivered earnings and revenue surprises of -9.52% and -100.00%, respectively, for the quarter ended September 2019.

Medicines Co. (MDCO) Reports Q3 Loss, Lags Revenue Estimates

The Medicines Company is near its 52-week high.

The Medicines Company A Buy On Inclisiran Data, With Caveats

Apellis Pharma

Syndax Pharmaceuticals

Needless to say, the biotech world has had a difficult 2019, with the SPDR S&P Biotech ETF (NYSE: XBI) down 20% from highs posted in April.

Baird Has 3 Top Biotech Picks With Huge Upcoming Potential Catalysts

The company's flagship cholesterol treatment shows major potential.

The Medicines Company Surges on Positive Drug Trial Results

The Medicines Company Is Up 161% Year to Date, but Here's a Better Way to Play the Drugmaker's Success

The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in the remaining two phase III studies in the ORION program. Shares up.

Medicines Company's Inclisiran Succeeds in Pivotal Studies

Medicines Company (MDCO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Medicines Company (MDCO) Jumps: Stock Rises 5.5%

The Medicines Company stock popped Wednesday after the biotech company unveiled positive results for its high cholesterol drug. Meanwhile, shares of partner Alnylam Pharmaceuticals dipped.

This Biotech Stock Could Add $5 Billion In Sales — Or Be Acquired

A detailed look at a big clinical trial did not disappoint.

Here's Why The Medicines Company Stock Soared Again on Tuesday

Conn's

Tilray Brands

These stocks managed to overcome a big market downdraft.

Why Tilray, Conn's, and Medicines Company Jumped Today

The Medicines Co. stock MDCO, +13.29% was reiterated as a Top Pick for 2019 at Chardan on Tuesday, with analyst Gbola Amusa highlighting the positive results from a late-stage trial of a treatment for cholesterol.

The Medicines Co. reiterated as Top Pick for 2019 at Chardan after positive results for cholesterol treatment

The Medicines Co. (NASDAQ: MDCO) shares made a handy gain on Tuesday after the firm announced results from its late-stage trial in the treatment of low-density lipoprotein cholesterol (LDL-C).

Why Medicines Co.’s Late-Stage LDL-Cholesterol Study Could Be a Big Hit

The Medicines Company (NASDAQ: MDCO) shares have been on a roll. After picking up some momentum Aug 21, the stock rallied strongly Aug.

Medicines Company Shares Reach 2-Year High Amid Positive Inclisiran Data

Shares of The Medicines Company jumped Tuesday after the biotech company's cholesterol treatment proved its mettle over 18 months. Alnylam Pharmaceuticals is partnered on the drug.

This Biotech Stock Is Looking To Leapfrog Its Rivals — And Buy Point

The Medicines Co. shares  rose 17% in premarket trade Tuesday, after the company said a late-stage trial of a cholesterol treatment met its main goals.

Medicines Co. shares rally 17% premarket on news of positive trial of cholesterol treatment

The Medicines Co. announced that the late-stage study, which used inclisiran to treat patients with ASCVD and elevated levels of bad cholesterol, had met on the primary and secondary endpoints.

The Medicines Co. Continues To Rack Up Milestones As It Heads Towards Regulatory Filings

The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in a pivotal study. Shares up.

Medicines Company's Inclisiran Succeeds in Pivotal Study

The biotech got good news on a clinical trial.

Here’s Why The Medicines Company Shares Jumped 13.8% Today

The Medicines Company (NASDAQ: MDCO) gave a sneak-peek of results from a late-stage trial of its proprotein convertase subtilisin/kexin type 9,or PCSK9 inhibitor inclisiran Monday morning ahead of presentation as a late-breaking science session Sept.

News for Medicines Stock (MDCO)